ERYTECH Pharma S.A.
ERYP · NASDAQ
12/31/2022 | 9/30/2022 | 6/30/2022 | 3/31/2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | -$470 | $3,077 | $9,184 | $8,116 |
| G&A Expenses | $3,017 | $3,795 | $2,137 | $4,938 |
| SG&A Expenses | $3,017 | $3,795 | $2,137 | $4,938 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$5,224 | -$1,306 | $422 | -$539 |
| Operating Expenses | -$2,677 | $5,566 | $11,743 | $12,515 |
| Operating Income | $2,678 | -$5,567 | $12,608 | -$12,515 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$62 | $531 | $2,016 | $604 |
| Pre-Tax Income | $2,616 | -$5,036 | $14,624 | -$11,911 |
| Tax Expense | -$3,318 | $102 | $3,737 | -$840 |
| Net Income | $5,936 | -$5,138 | $10,887 | -$11,911 |
| % Margin | – | – | – | – |
| EPS | 0.19 | -0.17 | 0.35 | -0.38 |
| % Growth | 211.8% | -148.6% | 192.1% | – |
| EPS Diluted | 0.19 | -0.17 | 0.35 | -0.38 |
| Weighted Avg Shares Out | 31,016 | 31,016 | 31,016 | 31,016 |
| Weighted Avg Shares Out Dil | 31,016 | 31,016 | 31,016 | 31,016 |
| Supplemental Information | – | – | – | – |
| Interest Income | $422 | $4,025 | -$835 | $841 |
| Interest Expense | $483 | $611 | $34 | $236 |
| Depreciation & Amortization | $421 | $4,010 | $2,050 | $840 |
| EBITDA | $3,520 | -$1,557 | $16,708 | -$10,835 |
| % Margin | – | – | – | – |